Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. P.V. Shekhar et al., Mol. Cancer Res., Oct 2006; 4: 729 - 745 | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | E. Xu et al., Mol. Cancer Res., 2014, 12(3):359-369, DOI: 10.1158/1541-7786.MCR-13-0526 | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | L. Qin et al., Cell Reports, 2015,13: 2056-2063; doi.org/10.1016/j.celrep.2015.11.015 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M. Mannefeld et al., Cancer Res., May 2009; 69: 4073 - 4080 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | B. Ljepoja et al., PLoS ONE, 2019, 14(11): e0224314, doi.org/10.1371/journal.pone.0224314 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | miRNA | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | B. Ljepoja, Dissertation, 2019, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | B. Ljepoja et al., Breast, 2019, 43, 31e38, https://doi.org/10.1016/j.breast.2018.10.007 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | A. M. Scherbakov et al., Frontiers in Pharmacology, 2018, 8:979, doi: 10.3389/fphar.2017.00979 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. Lang-Muritano et al., J. of Clinical Endocrinology & Metabolism, 2018, 103(10): 3748–3756 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | A. M. Scherbakov et al., Acta Naturae, 2015, 7(3): 133-1309 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | V. Morales-Garcia et al., FEBS Open Bio 10, 2020, 2541–2552, doi:10.1002/2211-5463.12987 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | C. Actis et al., Cancers, 2021, 13: 1252, doi.org/10.3390/cancers13061252 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | C. Thirukkumaran et al., PLOSONE 2017, DOI:10.1371/journal.pone.0168233 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | A. M. Scherbakov et al., Exp. Cell Res., 2013, 319: 3150 – 3159, doi.org/10.1016/j.yexcr.2013.08.019 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | H. Liu et al., J. Lipid Res., Mar 2013; 54: 776 - 785 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | stable transfection | K2 Transfection System | publication | B. Ljepoja et al., Scientific Reports, 2018, 8:6927, DOI:10.1038/s41598-018-25240-y | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | A.-K. Sommer et al., Oncotarget, 2016, 7 (31): 50461 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | B. Ljepoja, Dissertation, 2019, Ludwig-Maximilians-Universität München | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | I. V. Rassokhina et al., Steroids, 2016, 113: 29-37; doi.org/10.1016/j.steroids.2016.06.001 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | X. Ming et al., Am. Ass. for Cancer Res., 2018, DOI: 10.1158/1541-7786.MCR-18-0070 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | Z. Mbita, Dissertation, 2012, University of the Witwatersrand | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | K. J. Lee et al., Exp. Cell Research, 2015, 336: 211-222; doi.org/10.1016/j.yexcr.2015.07.010 |